Though NCOA3 mutations were a favorable prognostic factor in the combined cohort (Fig. 6A), NCOA3 mutations were predominant in colorectal cancer patients, followed by melanoma and bladder cancer patients (Fig. 6B). Here, NCOA3 is linked to melanoma.